即时询价 ×
* 必填项
请填妥以下表格,您将在一分钟内得到邮件机器人给你的报价。
Inquiry Online
×
* Required Fields.
Please complete the form below and we will contact you shortly.
Bulk Inquiry
×
* Required Fields.
Please complete the form below and we will contact you shortly.
CAS号 | 2750830-09-0 | 货号 | BCP49650 |
中文名 | Luxdegalutamide | ||
英文名 | Luxdegalutamide | ||
中文别名 | |||
英文别名 | ARV-766;ARV 766;ARV766; | ||
SMILES | CC1(C(C(C1OC2=CC(=C(C=C2)C#N)OC)(C)C)NC(=O)C3=CC=C(C=C3)N4CCC(CC4)CN5CCN(CC5)C6=CC(=C(C=C6)C(=O)NC7CCC(=O)NC7=O)F)C | ||
化学名称 | |||
分子式 | C45H54FN7O6 | 分子量 | 807.95 |
纯度 | 98% | 配送 | 惯例下常温包邮 |
产品描述 | Luxdegalutamide is an orally bioavailable androgen receptor (AR)-targeted protein degrader, composed of an AR ligand attached to an E3 ligase recognition moiety and utilizing the proteolysis targeting chimera (PROTAC) technology, with potential antineoplastic activity. Upon oral administration, luxdegalutamide targets and binds to the AR ligand binding domain on the AR. E3 ligase is then recruited to the AR by the E3 ligase recognition moiety of luxdegalutamide and the AR is tagged by ubiquitin. This causes ubiquitination and degradation of AR by the proteasome, and prevents the expression of AR target genes and halts AR-mediated signaling. This inhibits the proliferation of AR-overexpressing tumor cells. In addition, the degradation of the AR releases luxdegalutamide, allowing it to bind to additional AR. AR plays a key role in the proliferation of castration-resistant prostate cancer cells (CRPC). Luxdegalutamide may degrade resistance-driving point mutations of AR, including the L702H mutation associated with treatments including abiraterone. |
Tags:Luxdegalutamide 供应商,Luxdegalutamide 购买,Luxdegalutamide 生产,Luxdegalutamide 批量,Luxdegalutamide 供应,Luxdegalutamide 订购,Luxdegalutamide 采购